Role of PI3K/Akt/mTOR pathway in mediating endocrine resistance: concept to clinic

The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR...

Full description

Saved in:
Bibliographic Details
Published inExploration of targeted anti-tumor therapy Vol. 3; no. 2; pp. 172 - 199
Main Authors Skolariki, Aglaia, D’Costa, Jamie, Little, Martin, Lord, Simon
Format Journal Article
LanguageEnglish
Published Open Exploration 2022
Open Exploration Publishing Inc
Subjects
breast cancer
endocrine therapy
pi3k/akt/mtor pathway
Review
Online AccessGet full text

Cover

More Information
Summary:The majority of breast cancers express the estrogen receptor (ER) and for this group of patients, endocrine therapy is the cornerstone of systemic treatment. However, drug resistance is common and a focus for breast cancer preclinical and clinical research. Over the past 2 decades, the PI3K/Akt/mTOR axis has emerged as an important driver of treatment failure, and inhibitors of mTOR and PI3K are now licensed for the treatment of women with advanced ER-positive breast cancer who have relapsed on first-line hormonal therapy. This review presents the preclinical and clinical data that led to this new treatment paradigm and discusses future directions.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:2692-3114
2692-3114
DOI:10.37349/etat.2022.00078